Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that has antiangiogenic activity and improves progression-free survival in many solid malignancies when combined with cytotoxic chemotherapy, but has little effect on overall survival. Despite the effects of this drug in...
| 主要な著者: | , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
2010
|